Show simple item record

dc.contributor.advisorHiss, D.C.
dc.contributor.advisorAbdul-Rasool, Sahar
dc.contributor.authorAbrahams, Beynon
dc.date.accessioned2014-11-14T07:15:15Z
dc.date.available2014-11-14T07:15:15Z
dc.date.issued2014
dc.identifier.urihttp://hdl.handle.net/11394/3846
dc.descriptionMagister Scientiae (Medical Bioscience) - MSc(MBS)en_US
dc.description.abstractThis study investigated the effects of TKIs on the growth and proliferation of MCF-7 breast carcinoma cells in culture. MCF-7 cells were exposed to different concentrations of TKIs alone and in combination with each other. Inhibition of cell growth by TKIs used individually occurred in a dose- and time-dependent manner. When EGFR Inhibitor I, EGFR Inhibitor II/BIBX1382 and the multi-specific EGFR/ErbB-2/ErB-4 Inhibitor were used in combination with each other at equimolar log dose concentrations, the combined effects on cell growth was significantly different to inhibitors used individually as reflected in a decreased EC50 (IC50) during combination treatments. Generally, for the combinations with DOX, CPL and the TKIs, synergistic as well as antagonistic effects were observed at isoeffective concentrations with resultant decreases in dose reduction indices (DRIs) implying greater efficacies with the respective combinations. In this study, conventional PCR was used to detect and illustrate the presence of the EGFR gene in the samples, while RT-qPCR was used to determine the mRNA expression levels of this gene in MCF-7 breast carcinoma cellsen_US
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.subjectBreast canceren_US
dc.subjectHuman MCF-7 breast carcinoma cellsen_US
dc.subjectEpidermal growth factor receptoren_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.subjectDoxorubicinen_US
dc.subjectCisplatinen_US
dc.subjectEGFR inhibitor Ien_US
dc.subjectEGFR inhibitor II/BIBX1382en_US
dc.subjectEGFR/ErbB2/ErbB4 inhibitoren_US
dc.subjectDose-response curvesen_US
dc.subjectIC50/EC50en_US
dc.subjectDrug combination analysisen_US
dc.subjectSynergismen_US
dc.subjectAntagonismen_US
dc.subjectDose-reduction indicesen_US
dc.subjectHaematoxylin and eosin stainingen_US
dc.subjectAnnexin V-Cy3 fluorescent stainingen_US
dc.subjectApoptosisen_US
dc.subjectEGFR gene expression analysisen_US
dc.subjectReal-time qPCRen_US
dc.titleThe effects of various combinations of different classes of anticancer drugs and tyrosine kinase inhibitors on the human MCF-7 breast carcinoma cell lineen_US
dc.typeThesisen_US
dc.rights.holderUniversity of the Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record